Hilleman Laboratories, a Singapore-based joint venture between Merck (MRK) and global health charity Wellcome, is preparing to manufacture clinical-trial doses of an experimental vaccine targeting the Bundibugyo strain of Ebola, a variant for which no approved immunisation currently exists. For long-horizon...